Furthermore, inhibition of the non-canonical NF-κB pathway using an NF-κB inducing kinase (NIK) inhibitor in MCL and CLL reduced BCL-XL levels and led to increased vulnerability to venetoclax [38, 74]. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.